NHLBI Blood /Marrow Transplant Clinical Research Network

造血干细胞(HCT)移植为多种恶性和非霍奇金淋巴瘤提供了治疗方法。 非恶性疾病。它受到供体可获得性、移植相关毒性、移植物与宿主的关系等因素的限制。 疾病(GVHD)，恶性复发，感染，对一些患者来说，他们的后遗症减少 移植后的生活质量。与上一个供资时期相比继续取得进展，血液和 骨髓移植临床试验网络(BMT CTN)建议开发和实施 解决HCT关键问题的科学、有价值的前瞻性临床试验。我们将进行 多中心第二阶段，更重要的是，预期的第三阶段试验，涉及六个关键领域，包括： 替代供体和移植物来源；方案相关毒性；移植物抗宿主病；疾病复发；感染 和免疫重建；以及后遗症和生活质量。由于儿科疾病的复杂性 移植，特别是那些罕见的遗传性疾病，这些疾病很复杂，很难 研究中，我们将特别注意和集中科学知识来协调使用 网络的力量，以改善这一独特人群的BMT结果。BMT CTN将 还通过合作研究和辅助研究来扩大和利用网络资源 将与临床终点整合并与之互补的生物终点。网络将 也寻求与其他科学机构的积极合作，包括NCI资助的癌症合作社 团体为提高临床移植研究的效率为大量的患者 可以从BMT中受益，并最大限度地成功完成高质量和高优先级 临床试验。

Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and non-malignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post- transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials, in six key areas including: alternative donors and graft sources; regimen related toxicity; GVHD; disease recurrence; infection and immune reconstitution; and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve BMT outcomes for this unique population. The BMT CTN will also amplify and leverage Network resources through collaborative research and ancillary studies of biologic endpoints that will be integrated with and complement clinical endpoints. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials.